If only...
Dechra Pharmaceuticals (LSE: DPH) is a drugs company that specialises in the development of medical treatments for pets. Pet ownership is on the rise around the globe, as is spending on those pets, so Dechra is operating in a booming market.
Over the next three years, the firm's earnings per share is expected to more than double. Over the same time period, revenue is predicted to grow from £359m to £465m; profit, from £26m to £57m.
Be glad you didn't
Shire (LSE: SHP) is a biotechnology group with treatments for attention-deficit hyperactivity disorder and inflammatory bowel disease, among others. It has suffered from problems in the production of one of its best-selling drugs, Cinryze. Despite this, the firm has posted a 7% rise in sales to £3.7bn in the quarter to the end of September. Management is considering splitting the firm in two so it can focus more on developing medicines for rare diseases.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Watch out for fake Steven Bartlett video – you could lose thousandsScammers are trying to tap into the Trump tariffs chaos, but knowing what to look out for could save you thousands of pounds, says Kalpana Fitzpatrick
-
Can Donald Trump fire Jay Powell – and what do his threats mean for investors?Donald Trump has been vocal in his criticism of Jerome "Jay" Powell, chairman of the Federal Reserve. What do his threats to fire him mean for markets and investors?
-
Shire: a tempting buy-out betFeatures Pharmaceuticals firm Shire is set to be taken over – but it’s cheap even if the deal fails.
-
Three stocks to profit from the boom in pharma M&AOpinion Ailsa Craig picks three stocks that should capitalise on the M&A trend in the pharmaceutical sector, either as potential targets or as well-established acquirers of other rivals.
-
Pocket some grey pounds – three healthcare stocks to buy now
Opinion The ageing population is an opportunity for the health and medical sector. Here, professional investor Garry White picks three healthcare stocks to buy now.
-
UK stocks ahead as investor shrug off fresh oil price dropMarket Reports Investors have shrugged off concerns over the falling price of oil this morning ahead of the release of US earnings data.
